Oncogenic alterations in ERBB family members, including epidermal growth factor (EGF) and epidermal growth factor receptor 2 (EGFR2), promote cancer cell evasion of immune surveillance, thereby indirectly leading to an increase in the number of inflammatory cells in the TME (75). Here, EGFR is linked to cancer.